Craig-Hallum lowered the firm’s price target on Tandem Diabetes to $74 from $80 and keeps a Buy rating on the shares given a tough 2022 for the company. Following five years of rapid gains, Q4 results bring total 2022 revenue growth in at 15%, the firm notes. A layer beneath the top-line numbers, U.S. new pump growth was -9% year-over-year. The stock has understandably been punished for this declining sales growth and the last several quarters of earnings misses has shaken investor confidence, Craig-Hallum adds. The firm notes that Q4 was a bit more of a "boring" quarter, which it thinks investors will partially welcome.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TNDM:
- 3 Stocks to Buy Today, 2/24/2023, According to Top Analysts
- Tandem Diabetes price target lowered to $52 from $61 at Cowen
- Tandem Diabetes price target lowered to $40 from $45 at Baird
- Tandem Diabetes price target lowered to $71 from $76 at Barclays
- Tandem Diabetes sees FY23 revenue $885M-$900M, consensus $891.6M